Adaptimmune Therapeutics PLC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Adaptimmune Therapeutics PLC's Chief Financial Officer, Gavin Wood, sold 96,000 ordinary shares, eliminating his direct beneficial ownership of shares held as ADSs.
Adaptimmune Therapeutics PLC's Chief Operating Officer, William C. Bertrand Jr., sold 207,000 ordinary shares on August 28, 2025.
Adaptimmune Therapeutics PLC Director Ali Behbahani, through affiliated entities, has fully divested his indirect beneficial ownership of the company's ordinary shares.
EcoR1 Capital, a 10% owner and director of Adaptimmune Therapeutics PLC, reported the sale of over 64 million Ordinary Shares through pre-arranged Rule 10b5-1 plans across three days in late July 2025.
William C. Bertrand Jr., Chief Operating Officer of Adaptimmune Therapeutics PLC, acquired options to purchase ordinary shares in the company on February 20, 2025.
Form 4: Adaptimmune Therapeutics PLC: Chief Scientific Officer Acquires Options to Purchase Ordinary Shares
Joanna Elizabeth Brewer, Chief Scientific Officer of Adaptimmune Therapeutics PLC, reports the acquisition of options to purchase ordinary shares in the company.
John Lunger, Chief Patient Supply Officer of Adaptimmune Therapeutics PLC, was granted options to purchase ordinary shares in the company.
Cintia Piccina, Chief Commercial Officer of Adaptimmune Therapeutics PLC, reports the acquisition of options to purchase ordinary shares.
Elliot Norry, Chief Medical Officer of Adaptimmune Therapeutics PLC, reports acquisition of options to purchase ordinary shares.
Adaptimmune Therapeutics' CEO, Adrian Rawcliffe, reports the acquisition of options to purchase over 8.5 million ordinary shares in the company.
Adaptimmune Therapeutics' Chief Medical Officer, Elliot Norry, sold 5,584 American Depositary Shares (ADS) to cover tax obligations related to vested stock options.
John Lunger, Chief Patient Supply Officer at Adaptimmune Therapeutics, sold 5,584 American Depositary Shares (ADS) to cover tax obligations related to vested stock options.
Adaptimmune Therapeutics' Chief Operating Officer, William C. Bertrand Jr., sold 5,584 American Depositary Shares (ADS) to cover tax obligations related to vested stock options.
Adaptimmune Therapeutics CEO, Adrian Rawcliffe, sold 30,601 American Depositary Shares (ADS) to cover tax obligations related to vested share options.
Adaptimmune Therapeutics' CEO, Adrian Rawcliffe, sold American Depositary Shares (ADSs) to cover tax obligations related to the exercise of vested RSU-style share options.
Cintia Piccina, Chief Commercial Officer of Adaptimmune Therapeutics, exercised RSU-style share options and sold a portion of the acquired American Depositary Shares (ADS) to cover tax withholding obligations.
Elliot Norry, Chief Medical Officer of Adaptimmune Therapeutics PLC, sold American Depositary Shares (ADS) to cover tax withholding obligations related to the exercise of vested RSU-style share options.
John Lunger, Chief Patient Supply Officer of Adaptimmune Therapeutics PLC, sold American Depositary Shares (ADS) to cover tax obligations related to the exercise of vested RSU-style share options.
William C. Bertrand Jr., Chief Operating Officer of Adaptimmune Therapeutics PLC, sold American Depositary Shares (ADS) to cover tax obligations related to the exercise of vested RSU-style share options.
Director Ali Behbahani acquired options to purchase 1,144,686 ordinary shares of Adaptimmune Therapeutics PLC on July 1, 2024, at an exercise price of $0.16 per share.
Form 4: Adaptimmune Therapeutics Director Acquires Options to Purchase Over 1.5 Million Ordinary Shares
David M. Mott, a director of Adaptimmune Therapeutics PLC, acquired options to purchase 1,583,214 ordinary shares on July 1, 2024.
Form 4: Adaptimmune Therapeutics Director Acquires Options to Purchase Over 1 Million Ordinary Shares
Garry E. Menzel, a director of Adaptimmune Therapeutics PLC, reported acquiring options to purchase 1,121,604 ordinary shares on July 1, 2024.
Kristen Hege, a director of Adaptimmune Therapeutics PLC, acquired options to purchase 660,000 ordinary shares on July 1, 2024, at an exercise price of $0.16.
Form 4: Adaptimmune Therapeutics Director Acquires Options to Purchase Over 1.1 Million Ordinary Shares
Priti Hegde, a director of Adaptimmune Therapeutics PLC, acquired options to purchase 1,144,686 ordinary shares on July 1, 2024.
John Furey, a director of Adaptimmune Therapeutics PLC, reported acquiring options to purchase 660,000 ordinary shares on July 1, 2024.
Form 4: Adaptimmune Therapeutics Director Acquires Options to Purchase Over 1.2 Million Ordinary Shares
Lawrence M. Alleva, a director of Adaptimmune Therapeutics PLC, reported acquiring options to purchase 1,213,926 ordinary shares on July 1, 2024.
Andrew R. Allen, a director of Adaptimmune Therapeutics PLC, acquired options to purchase 660,000 ordinary shares on July 1, 2024.
Cintia Piccina, Chief Commercial Officer of Adaptimmune Therapeutics, sold shares to cover tax obligations related to the vesting of RSU-style share options.
Cintia Piccina, Chief Commercial Officer of Adaptimmune Therapeutics, reports the acquisition of options to purchase over 6 million ordinary shares.